"As we prepare for the establishment of the Group, we are cognisant of the inherent risks of such a broad reaching reform agenda and the need to balance this with the need for reform to speed up patient access to new medicines," said chief executive Liz de Somer.
Medicines Australia strikes cautious tone on HTA review implementation group
October 2, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Final days to help build Australia’s longest running life sciences benchmark survey
July 15, 2025 - - Latest News -
New Australian collaboration to build gene and cell therapy production
July 15, 2025 - - Latest News -
The need to correct a profound misconception of what ethical decision-making is and is not
July 15, 2025 - - Latest News -
Patient Voice Initiative announces the appointment of new president
July 15, 2025 - - Latest News -
HTA reform is fine, but why is the underpinning framework immutable?
July 15, 2025 - - Latest News -
Olympian joins call urging vigilance on meningococcal risk
July 15, 2025 - - Latest News -
Amplia Therapeutics announces additional confirmed partial response in ACCENT trial
July 14, 2025 - - Australian Biotech